Castle Biosciences, Inc.
A molecular diagnostics company that makes gene-based tests to help doctors judge how serious a skin cancer or tumor is and choose a course of care. Its best-known products, such as DecisionDx-Melanoma, are used to guide treatment for patients with melanoma and other skin conditions. Founded in 2007 by industry veteran Derek Maetzold and based in Friendswood, Texas, the company grew from the belief that a tumor's own biology can reveal more about a patient's outlook than routine clinical factors alone.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| RTW Investments, LP | 13G/APassive | 9.3% | 2.76M | May 15, 2026 |
| Roderick Wong | 13G/APassive | 9.3% | 2.76M | May 15, 2026 |
| Portolan Capital Management, LLC | 13G/APassive | 4.45% | 1.35M | May 15, 2026 |
| George McCabe | 13G/APassive | 4.45% | 1.35M | May 15, 2026 |
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 26, 2026 |
| Dimensional Fund Advisors LP | 13G/APassive | 3.9% | 1.14M | Jan 21, 2026 |
| WASATCH ADVISORS LP | 13G/APassive | 3.5% | 998.5K | May 12, 2025 |
| BlackRock, Inc. | 13G/APassive | 8.2% | 2.34M | Apr 23, 2025 |